To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.

H.R. 4730 would require pharmaceutical companies to include specific information about children on the labels of new drugs and biological products. To ensure safety and effectiveness, manufacturers would be required to conduct studies on how their products affect pediatric patients, including determining the correct dosages for different age groups.

For families, this bill aims to provide doctors and parents with clearer, science-based guidance on how medications work for children rather than relying on data from adult studies. While the bill allows for waivers if a drug is unlikely to be used by children or is unsafe for them, its primary goal is to reduce the risks associated with prescribing medications to minors by ensuring pediatric-specific data is available at the time of a drug's release.